ATE69062T1
(de)
*
|
1985-06-12 |
1991-11-15 |
Lubrizol Genetics Inc |
Modifiziertes zein.
|
JPS63502795A
(ja)
*
|
1985-10-03 |
1988-10-20 |
バイオジェン インコーポレイテッド |
顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、dna配列、組換えdna分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法
|
DE3851117T2
(de)
*
|
1987-10-16 |
1995-03-30 |
Genencor Int |
Sequenzspezifische saure E.coli-Protease.
|
US5328988A
(en)
*
|
1987-10-26 |
1994-07-12 |
Immunex Corporation |
Interleukin-7
|
US5714585A
(en)
*
|
1987-10-26 |
1998-02-03 |
Sterling Winthrop, Inc. |
Antibodies that are immunoreactive with interleukin-7
|
JPH03502322A
(ja)
*
|
1987-10-30 |
1991-05-30 |
イミュネックス・コーポレーション |
ヒトコロニー形成刺激因子の非グリコシル化類似体
|
WO1989010403A1
(fr)
*
|
1988-04-21 |
1989-11-02 |
Medvet Science Pty. Ltd. |
Variantes de gm-csf humain
|
WO1989010964A1
(fr)
*
|
1988-05-06 |
1989-11-16 |
Genentech, Inc. |
Nouvelle variante de facteur stimulant les colonies de granulocytes-macrophages bovins
|
EP0378666A4
(en)
*
|
1988-07-05 |
1992-01-22 |
Amgen Inc. |
Interleukin ii analogs
|
WO1992010570A1
(fr)
*
|
1990-12-13 |
1992-06-25 |
Immunex Corporation |
Recepteurs du facteur inhibiteur de la leucemie
|
EP0548012B1
(fr)
*
|
1991-12-16 |
1997-09-03 |
Novartis AG |
Endoprotéase dibasique recombinante localisée dans le réticulum endoplasmique et ses applications
|
US5463029A
(en)
*
|
1992-11-23 |
1995-10-31 |
Immunex Corporation |
Purification of fusion proteins comprising GM-CSF and IL-3
|
US5578301A
(en)
*
|
1993-12-14 |
1996-11-26 |
Sandoz Ltd. |
Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
|
KR101004174B1
(ko)
|
1995-06-29 |
2010-12-24 |
임뮤넥스 코포레이션 |
세포소멸을 유도하는 시토킨
|
DE69637942D1
(de)
|
1995-10-04 |
2009-07-09 |
Immunex Corp |
Stimulationsfaktor für dendriten
|
US5942253A
(en)
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
US6384203B1
(en)
|
1999-05-12 |
2002-05-07 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
US7153943B2
(en)
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
EP1012184B1
(fr)
*
|
1997-07-14 |
2007-10-10 |
Bolder Biotechnology, Inc. |
Derives d'hormone de croissance et proteines associees
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6846905B2
(en)
|
1997-08-15 |
2005-01-25 |
Abbott Laboratories |
Antigen constructs useful in the detection and differentiation of antibodies to HIV
|
EP2324857A1
(fr)
|
1997-09-08 |
2011-05-25 |
The General Hospital Corporation |
Agents d'imagerie destines a la détection précoce et au contrôle d'une plaque cardiovasculaire
|
US20040228834A1
(en)
*
|
1998-03-09 |
2004-11-18 |
Jeffrey Isner |
Compositions and methods for modulating vascularization
|
US6676937B1
(en)
*
|
1998-03-09 |
2004-01-13 |
Caritas St. Elizabeth's Medical Center Of Boston Inc. |
Compositions and methods for modulating vascularization
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
ES2321054T3
(es)
|
1999-01-19 |
2009-06-02 |
Molecular Insight Pharmaceuticals, Inc. |
Conjugados de factores estimulantes de colonias de granulocitos para direccionamiento y formacion de imagenes de infeccion e inflamacion.
|
TR200103266T2
(tr)
|
1999-05-13 |
2002-01-21 |
American Cyanamid Company |
Yardımcı kombinasyon formülasyonları
|
NZ521937A
(en)
*
|
2000-03-31 |
2004-08-27 |
Celgene Corp |
Inhibition of cyclooxygenase-2 activity
|
SG143058A1
(en)
*
|
2000-08-11 |
2008-06-27 |
Favrille Inc |
Method and composition for altering a t cell mediated pathology
|
US6911204B2
(en)
*
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
EE200300172A
(et)
*
|
2000-11-10 |
2003-06-16 |
Wyeth Holdings Corporation |
Antigeenne kompositsioon ja adjuvantsegu
|
WO2002064083A2
(fr)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthese de 3-amino-thalidomide et de ses enantiomeres
|
US20020169125A1
(en)
*
|
2001-03-21 |
2002-11-14 |
Cell Therapeutics, Inc. |
Recombinant production of polyanionic polymers and uses thereof
|
US7270960B2
(en)
|
2001-08-29 |
2007-09-18 |
Pacific Northwest Research Institute |
Diagnosis of ovarian carcinomas
|
AU2002366023B2
(en)
*
|
2001-11-19 |
2007-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
Drug mobilizing pluripotent stem cells from tissue into peripheral blood
|
GB0210741D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Medical Res Council |
Methods of therapy
|
NZ570777A
(en)
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
CN103393695A
(zh)
|
2002-05-17 |
2013-11-20 |
细胞基因公司 |
用于治疗和控制多发性骨髓瘤的方法及组合物
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
JP2006510606A
(ja)
*
|
2002-10-15 |
2006-03-30 |
セルジーン・コーポレーション |
骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
|
EP1900369A1
(fr)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Procédé d'utilisation et compositions comprenant des composés immunomodulateurs pour le traitement et la gestion de syndromes myélodysplasiques
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
AU2003284246A1
(en)
|
2002-10-16 |
2004-05-04 |
Samuel F. Hunter |
Method for treatment of demyelinating central nervous system disease using gm-csf
|
GB0224415D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Medical Res Council |
Compositions
|
MXPA05004780A
(es)
|
2002-11-06 |
2005-10-05 |
Celgene Corp |
Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
|
JP2006509770A
(ja)
*
|
2002-11-26 |
2006-03-23 |
アンソロジェネシス コーポレーション |
細胞治療学、細胞治療単位、およびそれらを利用した治療法
|
WO2004071283A2
(fr)
*
|
2003-02-13 |
2004-08-26 |
Anthrogenesis Corporation |
Utilisation de sang de cordon ombilical pour traiter des individus presentant une maladie, un trouble ou une pathologie
|
AU2004220457A1
(en)
|
2003-03-12 |
2004-09-23 |
Celgene Corporation |
7-amino- isoindolyl compounds amd their pharmaceutical uses
|
US7267960B2
(en)
|
2003-07-25 |
2007-09-11 |
Amgen Inc. |
Antagonists and agonists of LDCAM and methods of use
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
ZA200603718B
(en)
|
2003-11-06 |
2007-09-26 |
Celgene Corp |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
MXPA06006061A
(es)
*
|
2003-12-02 |
2006-08-11 |
Celgene Corp |
Metodos y composiciones para el tratamiento y manejo de la hemoglinopatia y la anemia.
|
EP1697399B1
(fr)
|
2003-12-12 |
2016-11-23 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS |
Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
|
BRPI0418742A
(pt)
*
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
WO2005110085A2
(fr)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Procedes d'utilisation et compositions comprenant des medicaments d'inhibition selective de cytokine, pour traiter et controler des syndromes myelodysplasiques
|
EP1768700B1
(fr)
*
|
2004-07-16 |
2010-12-15 |
Nektar Therapeutics |
Conjugues comprenant gm-csf et un polymer
|
US20080076729A1
(en)
*
|
2005-05-19 |
2008-03-27 |
Schering Aktiengesellachaft |
Interferon-beta gene therapy using an improved, regulated expression system
|
JP2008545639A
(ja)
*
|
2005-05-19 |
2008-12-18 |
バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト |
改善された調節発現系を用いる疾患の治療
|
DOP2006000117A
(es)
*
|
2005-05-19 |
2007-11-30 |
Schering Ag |
Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
GB0524103D0
(en)
*
|
2005-11-26 |
2006-01-04 |
Medical Res Council |
Healing
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
WO2007109583A2
(fr)
*
|
2006-03-17 |
2007-09-27 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Compositions et méthodes pour la prévention ou le traitement de maladie néoplasique chez un sujet mammalien
|
WO2007146335A2
(fr)
|
2006-06-12 |
2007-12-21 |
Sunesis Pharmaceuticals, Inc. |
Composés et compositions pour le traitement du cancer
|
US20080063642A1
(en)
|
2006-08-02 |
2008-03-13 |
Adelman Daniel C |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
AU2007315402B2
(en)
*
|
2006-11-03 |
2013-05-16 |
Drugrecure Aps |
Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
|
WO2008125222A2
(fr)
*
|
2007-04-11 |
2008-10-23 |
Bayer Schering Pharma Aktiengesellschaft |
Nouvelles molécules de modulation destinées à un système d'expression régulée amélioré
|
ES2617305T3
(es)
*
|
2007-07-17 |
2017-06-16 |
Acea Biosciences, Inc. |
Compuestos heterocíclicos y usos como agentes anticancerosos
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
US20110008371A1
(en)
|
2007-12-10 |
2011-01-13 |
Sunesis Pharmaceuticals, Inc |
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
|
RU2010148803A
(ru)
*
|
2008-04-30 |
2012-06-10 |
Ньютрон Роу (Bm) |
Способы применения кортикотропин-рилизинг фактора для лечения рака
|
ES2969144T3
(es)
|
2008-05-15 |
2024-05-16 |
Celgene Corp |
Formulaciones orales de análogos de citidina y métodos de uso de los mismos
|
WO2010055900A1
(fr)
|
2008-11-14 |
2010-05-20 |
ディナベック株式会社 |
Procédé de fabrication de cellules dendritiques
|
EP2248903A1
(fr)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages
|
EP2436387B1
(fr)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Composition pharmaceutique contenant crbn et son utilisation dans le traitement des maladies du cortex cerebral.
|
PE20120559A1
(es)
|
2009-06-24 |
2012-05-21 |
Stephen Evans-Freke |
Composicion que comprende al factor liberador de corticotropina
|
EP2498795B1
(fr)
|
2009-10-12 |
2016-12-07 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Granulysine dans l'immunothérapie
|
WO2011056566A2
(fr)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Composés et procédés pour traitement de cancer
|
US20110207751A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Long Mao |
Heterocyclic compounds and uses as anticancer agents
|
WO2011112933A1
(fr)
*
|
2010-03-12 |
2011-09-15 |
Celgene Corporation |
Procédés de traitement de lymphomes non hodgkiniens utilisant la lénalidomide, et biomarqueurs géniques et protéiques comme moyens de prédiction
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
WO2012093258A2
(fr)
|
2011-01-05 |
2012-07-12 |
Imperial Innovations Limited |
Traitement et criblage
|
EP2670396A1
(fr)
|
2011-01-31 |
2013-12-11 |
Celgene Corporation |
Compositions pharmaceutiques d'analogues de cytidine et leurs méthodes d'utilisation
|
EP2675911B1
(fr)
|
2011-02-17 |
2020-11-04 |
Fujirebio Diagnostics, Inc. |
Compositions et méthodes d'utilisation pour la détermination de he4a
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
AR085651A1
(es)
|
2011-03-11 |
2013-10-16 |
Celgene Corp |
Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
WO2013029627A1
(fr)
|
2011-08-29 |
2013-03-07 |
Trifoilium Aps |
Compositions et méthodes de traitement ou de prévention d'un dysfonctionnement pulmonaire induit par une radio- ou chimiothérapie
|
CA2853949A1
(fr)
|
2011-11-01 |
2013-05-10 |
Celgene Corporation |
Methodes de traitement de certains cancers utilisant des preparations orales d'analogues de la cytidine
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
WO2014004990A2
(fr)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Procédés pour déterminer l'efficacité d'un médicament en utilisant des protéines associées au céréblon
|
US20150174204A1
(en)
|
2012-07-20 |
2015-06-25 |
Reponex Pharmaceuticals Aps |
Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
|
WO2014022759A1
(fr)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Agents modulant l'activation des cellules immunitaires et procédés de leur utilisation
|
TW201408657A
(zh)
|
2012-08-09 |
2014-03-01 |
Celgene Corp |
(s)-3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)哌啶-2,6-二酮之鹽及固態形式、包含其之組合物及其使用方法
|
EP2882442B1
(fr)
|
2012-08-09 |
2021-06-09 |
Celgene Corporation |
Procédés de traitement du cancer à l'aide de 3-(4-((4-(morpholinométhyl)benzyl)oxy)-1-oxo-iso-indolin-2-yl)pipéridine-2,6-dione
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
BR112015005243A2
(pt)
|
2012-09-10 |
2017-07-04 |
Celgene Corp |
métodos para o tratamento de câncer de mama localmente avançado
|
WO2014128173A1
(fr)
|
2013-02-20 |
2014-08-28 |
Trifoilium Aps |
Gm-csf dans le traitement de la mucosite buccale chronique
|
US9968627B2
(en)
|
2013-03-26 |
2018-05-15 |
Celgene Corporation |
Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
|
JP6469077B2
(ja)
|
2013-04-02 |
2019-02-13 |
セルジーン コーポレイション |
4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
|
EP3293275B1
(fr)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions et procedes d'identification,d'evaluation, de prevention et de traitement du cancer en utilisant des isoformes pd-l1
|
EP2815749A1
(fr)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
EP3094736A4
(fr)
|
2014-01-14 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1
|
US20170035850A1
(en)
|
2014-03-07 |
2017-02-09 |
Reponex Pharmaceuticals Aps |
Compositions for treating lung infections by airway administration
|
EP2940128A1
(fr)
|
2014-04-30 |
2015-11-04 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Adénovirus comprenant une fraction de liaison à l'albumine
|
WO2015195634A1
(fr)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Méthode de traitement contre les cancers associés au virus d'epstein-barr (ebv) utilisant des formulations de 5-azacytidine par voie orale
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
WO2016012608A1
(fr)
|
2014-07-24 |
2016-01-28 |
Reponex Pharmaceuticals Aps |
Compositions comprenant le facteur de stimulation des colonies de granulocytes-macrophages pour le traitement d'une maladie inflammatoire de l'intestin
|
HUE061382T2
(hu)
|
2014-08-22 |
2023-06-28 |
Celgene Corp |
Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
|
EP3313818B1
(fr)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs
|
WO2017066561A2
(fr)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
ES2956767T3
(es)
|
2016-01-08 |
2023-12-27 |
Celgene Corp |
Formulaciones de 2-(4-clorofenil)-N-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
|
HUE051231T2
(hu)
|
2016-01-08 |
2021-03-01 |
Celgene Corp |
Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
|
CN108712904B
(zh)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
|
US20210309965A1
(en)
|
2016-03-21 |
2021-10-07 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
JP7014731B2
(ja)
|
2016-04-01 |
2022-02-01 |
シグナル ファーマシューティカルズ,エルエルシー |
置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
|
SI3436019T1
(sl)
|
2016-04-01 |
2021-12-31 |
Signal Pharmaceuticals, Llc |
(1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe
|
WO2017189754A1
(fr)
*
|
2016-04-26 |
2017-11-02 |
Salk Institute For Biological Studies |
Thérapies par virus oncolytiques de hsv-1 qui ciblent des cancers alt-dépendants
|
EP3485002A4
(fr)
|
2016-07-13 |
2020-07-29 |
Ohio State Innovation Foundation |
Plateformes et procédés pour l'optimisation de la présentation de l'antigène par l'hôte, et immunité anti-tumorale et anti-infectieuse de l'hôte
|
WO2018013689A1
(fr)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Dispersions solides et formes solides comprenant du 4-amino-2-(2,6-dioxopipéridine-3-yl)isoindoline-1,3-dione, et procédé de préparation et utilisation de ces dernières
|
WO2018013693A1
(fr)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser
|
US20180258064A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
CA3066939A1
(fr)
|
2017-06-21 |
2018-12-27 |
SHY Therapeutics LLC |
Composes interagissant avec la superfamille ras destines a etre utilises dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
|
PL3644999T3
(pl)
|
2017-06-30 |
2023-05-08 |
Celgene Corporation |
Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu
|
WO2019070827A1
(fr)
|
2017-10-04 |
2019-04-11 |
Celgene Corporation |
Procédés de préparation de cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-méthylcyclohexane-1-carboxamide
|
IL273658B1
(en)
|
2017-10-04 |
2024-06-01 |
Celgene Corp |
Compounds and methods for using cis-4-[2-{[(3S,4R)-3-fluoroxan-4-YL]amino}-8-(2,4,6-trichloroanilino)-9H-purine-9-YL]- 1-Methylcyclohexane-1-carboxamide
|
KR20200100603A
(ko)
|
2017-10-16 |
2020-08-26 |
드럭리큐어 에이피에스 |
불응성 비-결핵성 마이코박테리아 감염을 치료하기 위한 gm-csf
|
AU2018360766A1
(en)
|
2017-11-06 |
2020-05-21 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
WO2019147982A1
(fr)
|
2018-01-26 |
2019-08-01 |
Celldex Therapeutics, Inc. |
Méthodes de traitement du cancer à l'aide d'agents mobilisateur de cellules dendritiques
|
WO2020132071A1
(fr)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
|
US11964001B2
(en)
|
2019-04-09 |
2024-04-23 |
Washington University |
Compositions for treating or preventing respiratory tract infections and method of use thereof
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
WO2023201282A1
(fr)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Nouveaux composés gspt1 et procédés d'utilisation des nouveaux composés
|
WO2024064646A1
(fr)
|
2022-09-20 |
2024-03-28 |
Celgene Corporation |
Sels et formes à l'état solide de (s)- ou 3-(4-((4-(morpholinométhyl)benzyl)oxy)-1-oxoisoindolin-2-yl)pipéridine-2,6-dione racémique et leurs procédés d'utilisation
|